Key Takeaways
- Record quarter, broad-based growth: Revenue hit INR940 crores, with U.K./Europe up 65% YoY, North America at a record, and Australia/New Zealand up 64%, reducing dependence on any single geography.
- Gross margin compressed sequentially as flagged: Gross margin fell from 59.1% to 58.5% QoQ as lower-cost inventory was consumed, while freight costs nearly doubled and employee costs rose on team investments.
- PAT dipped on non-operational charges: PAT declined to INR144 crores from INR159 crores QoQ, driven by higher depreciation from a change in intangible asset accounting, lower other income, and a higher tax rate, not by operational weakness.
- Cash generation transformed: H1 cash from operations jumped to INR322 crores from INR75 crores YoY, with cash conversion improving to 75.2% and net cash rising to INR1,095 crores even after acquisitions and dividends.
- What to watch next quarter: Whether the U.S. cold season delivers the seasonal volume uplift, the pace of ROW shipment recovery as Red Sea disruptions ease, and any movement on the manufacturing capacity expansion dialogue.
U.K. and Europe: The Growth Engine Fires
- U.K. rebound: Revenue grew 65% YoY to ~INR405 crores after a subdued FY26, with organic growth at 49% ex-acquisitions; the company used the flat period to strengthen its portfolio and prepare new product launches.
- Sustainability anchored in pipeline: Growth is sustainable because of product pipelines and visibility on approvals, with many products under filing, registration, and approval; management expects quite a few approvals every quarter to unfold new revenue streams.
- European infrastructure build-out: The company is building its own commercial infrastructure in key European markets to get closer to customers and control portfolio go-to-market; QliniQ (Netherlands) contributed ~INR84 crores in H1, while ABCnow and Marksans GmbH are strengthening the German platform.
- M&A appetite active: Exploring more M&A in Europe, hoping to conclude a couple within the next 12 months; the strategy is country-centric inorganic expansion, with both the Netherlands and Germany seen as having significant potential.
- Five-year ambition intact: The INR1,000 crore Europe top-line target in five years remains valid; Europe is expected to shape up very well over the next three years and become a prominent contributor to overall objectives.
Mark Saldanha: "Pretty much, like I've always said, you have got to just wait for the business model sometimes to unfold."
North America: Steady Despite Consumer Headwinds
- Record quarter with single-digit price erosion: North America delivered its highest ever quarterly revenue of INR421 crores, growing 8.7% YoY; price erosion in prescription products remained in single digits, and the order book continues to build.
- Seasonal tilt yet to kick in: A substantial portion of the U.S. portfolio is seasonal, tilted toward the cold season (October to December); that season had not yet fully kicked in during Q2, leaving volume upside for H2.
- Consumer affordability pressure: Geopolitical scenarios, inflation, and crude oil are impacting affordability, with medicines becoming a lower priority versus food and gas; this weighs on near-term demand but has not derailed the medium-term thesis.
- Order book ambition reiterated: Management remains optimistic and still believes the U.S. order book will increase from $225 million to $300 million within the next three years; 5 to 6 ANDA filings are expected by March.
- OTC store brand push: Ambition to double U.S. store brand OTC revenue, supported by an expanding product pipeline; the company is already positioned with some retailers as a strategic product development and supply chain partner, discussing first-to-market launches and innovations.
Mark Saldanha: "Obviously, with costs going up, I think medicines are literally the last priority on everyone's mind. Obviously, food and gas become the top priority for everyone else."
Australia and New Zealand: The Nova Engine
- 64% YoY growth, all organic: Revenue grew to ~INR101 crores, all through the Nova subsidiary which handles front-end marketing for all products; the branded prescription business strategy is gaining traction, with the Rx division growing at a strong pace.
- $100 million subsidiary ambition: Management expects Australia to grow to a $100 million subsidiary over the next three years, with growth meaningfully ahead of previous year levels.
- Nasal spray manufacturing shift: Nasal sprays have been launched in Australia and are currently outsourced, but will soon be manufactured in-house, adding a new dosage form capability.
Rest of World: Geopolitical Drag, Gradual Recovery
- Shipment disruptions, not demand destruction: Revenue was impacted by ongoing geopolitical disruptions in the Middle East and other regions affecting the timing of certain shipments; management characterized this as largely operational and timing-related, not a change in underlying opportunities.
- Red Sea logistics chaos easing slowly: The first half was a struggle due to transportation issues, vessels stuck in the Red Sea, and supply chain chaos; this is slowly easing, with better movement seen in the last month, though the company cannot fully recover six months of lost ground.
- Conditional recovery path: If conditions ease, INR20 to 25 crore per quarter is doable, and the company expects to be on track by year-end to come back to what was envisaged; Access Healthcare (Dubai) is holding its own and remains profitable and cash-generative.
Mark Saldanha: "If you had asked me this question maybe a quarter back, I never thought the war would last this long. I was hoping that the war would be over before the election because of the pressure of the election, but who knows? It didn't happen, so maybe I don't have a crystal ball to predict on geopolitical scenarios."
Margins and Costs: Operating Leverage Absorbs Shocks
- Gross margin walk: Gross margin improved 135 bps YoY to 58.5%, but declined sequentially from 59.1% as Q1 benefited from consumption of lower-cost inventory and Q2 saw an increase in inventory costs.
- Freight and people costs rose: Freight costs nearly doubled in the current environment, contributing approximately INR20 crores to the sequential increase in other expenses; employee costs rose ~INR8 crores sequentially due to team strengthening and investment in newer markets.
- EBITDA margin held at 22.8%: Despite higher freight, employee costs, and German startup costs of a couple of crores, the company delivered record quarterly EBITDA and maintained a 22.8% margin, reflecting operating leverage, improving product and geography mix, and disciplined execution.
- PAT dip is non-operational: The sequential PAT decline from INR159 crores to INR144 crores was primarily due to higher depreciation and amortization following a change in accounting treatment for intangible assets (now depreciated over 10 years), lower other income as currency movements stabilized, and a higher effective tax rate of 25.8%.
- Gross margin outlook: Management expects to maintain gross margin at 55% to 56%; if crude and raw material prices come down, gross margin will increase back to historic numbers, and retailers will not ask for price cuts in that scenario.
Mark Saldanha: "I think our EBITDA should be pretty much in the range of 21%-22%, whatever we performed this year, this quarter. I do see our overall EBITDA being in that same range."
Capital Allocation and Capacity: Building for INR5,000 Crores
- Net cash fortress: Net cash increased by INR135 crores during H1 to INR1,095 crores, even after ~INR95 crores on acquisitions and ~INR41 crores on dividends; cash conversion improved to 75.2% from 30.7% YoY.
- Manufacturing capacity expansion in motion: Planning for INR5,000 crores revenue, the company is looking at adding another manufacturing block within the existing Teva plant facility and acquiring a plant; in active dialogue on both fronts, with a timeline of approximately 12 months to a year and a half.
- Acquisition focus on dosage forms: Looking at different dosage forms beyond injectables, expanding where capacity constraints are foreseen in about two years; tablets and solid oral could be part of it, and the company will always ensure a solid oral block around any acquisition.
- No backward integration: Not getting into API or backward integration as of now, given the global situation.
- Capital allocation priorities: Allocating capital on capex and M&A, with M&A focus in Europe and manufacturing facilities in India; a buyback is always an option and will be evaluated if nothing else materializes.
- Existing capacity sufficient near-term: Current capacity is good for the next two to three years on oral solids, but the company always wants additional capacity.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue ambition | Trending toward INR5,000 crores | Next three years |
| Revenue ambition | Doubling revenue from FY26 base to ~INR6,000 crores | Next five years |
| U.S. order book | Increase from $225 million to $300 million | Next three years |
| Australia subsidiary | Grow to a $100 million subsidiary | Next three years |
| Europe top line | Reach INR1,000 crores | Five years (target still valid) |
| FY28 revenue | INR4,000 crores | FY28 (next year) |
| Full-year EBITDA margin | 21% to 22% range | FY27 |
| Gross margin | Maintain at 55% to 56% | Ongoing; upside if raw material prices cool |
| U.S. ANDA filings | File another 5 to 6 ANDAs | By March (next couple of months) |
| European M&A | Hoping to conclude a couple of acquisitions | Next 12 months |
| Manufacturing capacity addition | Add blocks or acquire a plant | Approximately 12 months to 1.5 years |
| Depreciation run rate | Current increased level is the going run rate | Next couple of quarters |
| Dividend | Broadly in line with historical ~1/3 of free cash flow | FY27 (formal evaluation pending) |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹940 cr, +30.5% YoY and +11.8% QoQ |
| Total income | ₹958 cr, +29.2% YoY |
| Gross margin | 58.5%, +135 bps YoY; declined from 59.1% in Q1 |
| EBITDA | ₹214 cr, +48.3% YoY |
| EBITDA margin | 22.8%, +274 bps YoY; ahead of 20–21% guidance range |
| Profit before tax | ₹194 cr, +45.1% YoY |
| Profit after tax | ₹144 cr, +44.8% YoY; net margin 15% |
| Effective tax rate | 25.8% |
| North America revenue | ₹421 cr, 44.8% of total, +8.7% YoY |
| U.K. and Europe revenue | ₹405 cr, 43% of total, +65% YoY; organic growth ex-acquisitions 49% |
| Australia and New Zealand revenue | ₹101 cr, 10.7% of total, +64% YoY |
| Rest of World revenue | ₹14 cr, 1.5% of total |
| U.S. order book | $225 mn, target to reach $300 mn within three years |
| Cash generated from operations (H1) | ₹322 cr, vs ₹75 cr in H1 FY26; cash conversion 75.2% |
| Free cash flow (H1) | ₹275 cr, after capex of ₹46 cr |
| Net cash position | ₹1,095 cr as of Sep end; net worth ₹3,367 cr |
| Working capital cycle (H1) | ~128 days, reduced from 138 days in FY26 |
| R&D expenditure (H1) | 2.6% of revenue |
| OTC vs Rx mix | ~75% OTC, ~25% Rx |